NCI National Clinical Trials Network (NCTN) Program Guidelines

More documents

Recommendations

Info

NCTN Program Guidelines Table of Contents PART 1: OVERVIEW OF THE NCTN PROGRAM ...................................................................................................................... 14 I. INTRODUCTION ................................................................................................................................................................ 14 A. Purpose and Content of Guidelines ......................................................................................................................... 14 B. Background, Overview, and Purpose of the NCTN Program.................................................................................... 14 C. Overall Goal of the NCTN Program ......................................................................................................................... 15 D. Anticipated Organization of Key Components of the NCTN Program ...................................................................... 15 1. Network Group Operations Centers .......................................................................................................................................16 2. Network Group Statistics and Data Management Centers .....................................................................................................16 3. Network Group Integrated Translational Science Centers ......................................................................................................17 4. Network Lead Academic Participating Sites ...........................................................................................................................17 5. Network Radiotherapy and Imaging Core Services Centers ....................................................................................................17 6. Canadian Collaborating Clinical Trials Network ......................................................................................................................17 7. Interactions with Other NCI-supported Programs ..................................................................................................................17 7.1 NCI Clinical Trials Tumor Banks................................................................................................................................................. 17 7.2 NCI Community Clinical Oncology Programs (CCOPs) & Minority-Based CCOPs (MB-CCOPs).................................................. 18 7.3 NCI Cancer Trials Support Unit (CTSU) ...................................................................................................................................... 18 7.4 NCI Central Institutional Review Boards (CIRBs) ....................................................................................................................... 19 7.5 NCI Advisory & Scientific Committees ...................................................................................................................................... 19 7.5.1 NCI Clinical Trials and Translational Research Advisory Committee (CTAC) ..................................................................... 20 7.5.2 NCI Scientific Steering Committees (SSCs) ....................................................................................................................... 20 7.5.3 NCI Clinical and Translational Research Operations Committee (CTROC) ........................................................................ 20 II. GOALS OF NCTN RESEARCH ............................................................................................................................................... 22 A. Clinical Treatment Trials & Advanced Imaging Trials .............................................................................................. 22 B. Ancillary Studies ..................................................................................................................................................... 22 C. Cancer Control, Symptom Management, Prevention, and Quality of Life Studies ................................................... 22 D. Collaborations Among Network Group and with Other Organizations on Clinical Trials ......................................... 23 E. NCTN Clinical Trials Originating from Outside the Network Groups ........................................................................ 23 F. Conduct of NCTN Clinical Research ......................................................................................................................... 23 III. GENERAL MANAGEMENT & NETWORK OPERATING AND FUNDING PRINCIPLES .............................................................................. 24 A. General Management ............................................................................................................................................ 24 B. NCTN Leadership Management Committee ............................................................................................................ 24 C. Network Operating Principles ................................................................................................................................ 25 1. Access to NCTN Trials & Crediting for Patients Accrual to Trials .............................................................................................25 2. Submission of Data and Biospecimens for NCTN Trials ...........................................................................................................25 3. Use of the NCI Central Institutional Review Board .................................................................................................................25 4. Trial Proposals Originating From Outside the Network Groups ..............................................................................................26 Page 2 of 241
NCTN Program Guidelines Table of Contents D. Network Funding Principles .................................................................................................................................... 26 1. Grant Funding for Key Components of the NCTN Program .....................................................................................................26 2. Funding for Data Collection/Management & Biospecimen Collection on “Per Case” Basis .....................................................27 2.1 Network Lead Academic Participating Sites Funding .............................................................................................................. 27 2.2 CCOPs and MB-CCOPs Funding ............................................................................................................................................... 27 2.3 Pediatric Network Group Member Institutions/Sites Funding ................................................................................................ 27 2.4 Adult Network Group Member Institutions/Sites Funding ..................................................................................................... 28 2.5 Categories of “Per Case Management” Funding ..................................................................................................................... 28 2.6 Notification of “Per Case Management” Funding for Trials .................................................................................................... 30 3. Program Income for Key Components of the NCTN Program..................................................................................................30 IV. TERMS & CONDITIONS OF AWARD FOR COOPERATIVE AGREEMENTS FOR NCTN PROGRAM KEY COMPONENTS .................................... 32 A. General Terms and Conditions of Award for All Key Components of the NCTN Program ........................................ 32 1. General Programmatic Responsibilities .................................................................................................................................32 2. Program Director(s)/Principal Investigator(s) Primary Responsibility & Program Income Reporting ......................................32 3. NIH Staff Programmatic Responsibility ..................................................................................................................................33 4. Joint Responsibility ................................................................................................................................................................34 5. Dispute Resolution ................................................................................................................................................................34 B. Specific Terms and Conditions of Award for the Key Components of the NCTN Program ........................................ 36 1. Specific Awardee Rights & Responsibilities - Network Group Operations Centers ..................................................................36 1.1 Clinical Trial Development Program ......................................................................................................................................... 36 1.1.1 Overall Research Strategy ................................................................................................................................................ 36 1.1.2 Scientific Research and Administrative Committees ........................................................................................................ 36 1.1.3 Young Investigator Mentoring/Training: .......................................................................................................................... 37 1.1.4 Communications Support ................................................................................................................................................. 37 1.1.5 Publications ...................................................................................................................................................................... 38 1.1.6 Data Rights ....................................................................................................................................................................... 39 1.2 Member Site Accrual Program ................................................................................................................................................. 39 1.3 Operational Management ........................................................................................................................................................ 41 1.3.1 Governance, Organizational Structure, Policies & Procedures, and Membership ............................................................ 41 1.3.2 Development of Study Proposals & Protocols for Clinical Trials ...................................................................................... 42 1.3.3 Conduct of Clinical Trials ................................................................................................................................................. 43 1.3.4 Quality Assurance and Onsite Auditing ........................................................................................................................... 47 1.3.5 Financial Management .................................................................................................................................................... 49 1.4 Program for Collaborations and Participation in Collective Management .............................................................................. 50 1.5 Compliance with Federal Regulations for Clinical Research & Resource Sharing Plans .......................................................... 50 1.5.1 Office for Human Research Protection (OHRP) Assurances ............................................................................................. 50 1.5.2 IRB Review of NCTN Trials by Member Institutions/Sites ................................................................................................ 50 1.5.3 Assurance of Appropriate Informed Consent by Member Institutions/Sites ................................................................... 50 1.5.4 IRB Review of the Network Group Operations Center ..................................................................................................... 51 1.5.5 Inclusion of Women, Minorities, and Children in Clinical Research ................................................................................. 51 1.5.6 Data and Safety Monitoring Policy and Plans ................................................................................................................... 52 1.5.7 Resource Sharing Plans .................................................................................................................................................... 52 1.5.8 Education on the Protection of Human Subjects ............................................................................................................. 53 1.5.9 Other Federal Regulations ................................................................................................................................................ 53 1.6 Conflict of Interest Policy ........................................................................................................................................................ 53 1.7 Special Requests for Use of the NCTN Program Infrastructure Services ................................................................................. 53 Page 3 of 241
Page 1: NATIONAL CANCER INSTITUTE NATIONAL
Page 5 and 6: NCTN Program Guidelines Table of Co
Page 15 and 16: PART 1: Overview of NCTN Program Se
Page 23 and 24: PART 1: Overview of the NCTN Progra
Page 53 and 54:
PART 1: Overview of NCTN Program Se
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
PART 2: Submission of Competing New
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
PART 2: Submission of New/Competing
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
PART 3: Submission of Non-Competing
Page 189 and 190:
TYPE OF STUDY PART 3: Submission No
Page 191 and 192:
PART 3: Submission Non-Competing Ap
Page 193 and 194:
PART 3: Submission Non-Competing Ap
Page 195 and 196:
PART 4: Appendices Section II - Req
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Participating Site Member Category
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
PART 4: Appendices Section IV - Cos
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
PART 4: Appendices Section V - Impo
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Part 4: Appendices - VI. Sample Tab
Page 225 and 226:
Part 4: Appendices - VII. Model for
Page 227 and 228:
Part 4: Appendices - VII. NCTN Prog
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Part 4: Appendices - IX. Common Bud
Page 235 and 236:
Part 4: Appendices - IX. Common Bud
Page 237 and 238:
Part 4: Appendices - VII. Accrual I
Page 239 and 240:
Part 4: Summary of Updates to Guide
Page 241:
Part 4: Summary of Updates to Guide
show all

NCI National Clinical Trials Network (NCTN) Program Guidelines

Create successful ePaper yourself

Delete template?

Save as template?